Drug Sponsors

Regado Biosciences secures $51M Series E financing

Wednesday, December 19, 2012 10:13 AM

Regado Biosciences, a Basking Ridge, N.J.-based private biopharmaceutical company developing antithrombotic aptamers with active control agents, has secured a landmark $51 million Series E financing. 

More... »

Teva signs new $3B syndicated revolving credit facility

Tuesday, December 18, 2012 02:23 PM

Teva Pharmaceutical Industries, a global pharmaceutical company, has entered into a new five-year, $3 billion unsecured revolving credit facility, which replaces its existing $2.5 billion credit facility.

More... »

Takeda sells non-Colcrys URL Pharma to Sun Pharmaceutical

Tuesday, December 18, 2012 10:13 AM

Takeda Pharmaceuticals U.S.A. has entered into a definitive agreement to sell the non-Colcrys (colchicine, USP) URL Pharma generic business to Caraco Pharmaceutical Laboratories, a wholly-owned subsidiary of Sun Pharmaceutical Industries.

More... »

Soligenix acquires novel innate defense regulator clinical program

Tuesday, December 18, 2012 09:44 AM

Soligenix, a Princeton, N.J.-based development stage biopharmaceutical company, has acquired a novel drug technology, known as SGX94, representing a unique approach to modulation of the innate immune system. 

More... »

Bio-Rad to acquire MorphoSys's research & diagnostics antibody business

Tuesday, December 18, 2012 09:16 AM

MorphoSys, a German biotech focused on human antibodies, has agreed to sell its research and diagnostic antibody segment AbD Serotec to Bio-Rad Laboratories, a multinational manufacturer and distributor of life science research and clinical diagnostic products.

More... »

Promedior opens new office and labs in Lexington, Mass.

Monday, December 17, 2012 03:34 PM

Promedior, a clinical stage biotechnology company focused on fibrosis, is opening its new office and laboratory space at 101 Hartwell Avenue, Lexington, Mass.

More... »

Vivalis, Intercell merge to create Valneva

Monday, December 17, 2012 03:06 PM

The management boards of Vivalis, a biopharmaceutical company focused on cell-based solutions, and Intercell, a vaccine-biotechnology company, have agreed to the terms of a merger to create the newly-named Valneva, a European biotechnology company in vaccines and antibodies.

More... »

Teva, Handok to establish business venture in Korean pharma market

Monday, December 17, 2012 01:41 PM

Teva Pharmaceutical Industries, an Israel-based pharmaceutical company, and Handok Pharmaceuticals, a pharmaceutical/healthcare company in Korea, have agreed to establish a business venture in South Korea, allowing Teva to gain entrance into the Korean pharmaceutical market, currently valued at approximately $14 billion.

More... »

Naurex completes $38M Series B financing

Monday, December 17, 2012 12:03 PM

Naurex, an Evanston, Ill.-based clinical-stage company focused on developing treatments for CNS disorders, has completed a $38 million Series B financing led by new investor Baxter Ventures. 

More... »

Catalent, UMN Pharma collaborate on biosimilar development, production in Japan

Monday, December 17, 2012 11:35 AM

Catalent Pharma Solutions, a Somerset, N.J.-based developer of solutions and drug delivery technology, has signed an agreement to provide UMN Pharma, a Japanese pharmaceutical company, a broad range of biosimilar cell lines using Catalent's proprietary GPEx technology.

More... »